The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
India's Zydus Lifesciences has been barred by the Delhi High Court from selling its breast cancer drug, Sigrima, a biosimilar version of Roche's pertuzumab (brand name Perjeta). 12 July 2024
The clinical trial landscape for chronic lymphocytic leukemia (CLL) shows a robust global effort to advance treatment options and understand the disease, according to a report. 12 July 2024
As part of an ongoing organizational restructuring effort, Swiss pharma giant Novartis (NOVN: VX) will reportedly close an R&D site in San Diego, USA, leading to job losses. 12 July 2024
Henry Pelish has continued his rise up the ranks at Nuvalent, a Boston-based biopharma focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. 11 July 2024
The US Food and Drug Administration (FDA) has granted Fast Track designation for AB-1005, which is being developed for moderate Parkinson’s disease by German pharma major Bayer gene therapy subsidiary Asklepios BioPharmaceutical (AskBio). 11 July 2024
French drugmaker Ipsen has entered into an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential, from China-based Foreseen Biotechnology. 11 July 2024
German drug discovery and development company Evotec has entered into a multi-year master research collaboration and option and license agreement with US pharma giant Pfizer. 11 July 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024